Zamora-Barrón M, Aguilar-Salinas CA, Hernández-Jiménez S, Gómez-Pérez FJ, Rull-Rodrigo JA

Language: Spanish
References: 22
Page: 46-50
PDF size: 82.75 Kb.

ABSTRACT

Familial combined hyperlipidemia (FCHL) is the most common primary dyslipidemia. It shares some characteristics with the metabolic syndrome. Objective: To describe the prevalence of the metabolic syndrome in FCHL cases. Methods: FCHL subjects from the outpatient Lipid Clinic of (n = 102) of a tertiary care center were included. The FCHL diagnosis was established if hypertriglyceridemia (> 150 mg/dL) and/or hypercholesterolemia (> 200 mg/dL) were found in the proband and at least 2 first degree relatives. The definition of the metabolic syndrome provided by the National Cholesterol Education Program was used. A clinical evaluation and blood tests were done in every case. Data are presented as mean ± standard deviation. Results: Patients characteristics were: age 54 ± 15 years, body mass index 28.3 ± 6.5 kg/m2 (27.5% were obese) and 58% were females. The lipid profile was typical of FCHL: cholesterol 232.7 ± 59.8 mg/dL, triglycerides 311 ± 198 mg/dL, HDL-C 39.4 ± 12 mg/dL, LDL-C 144.5 ± 60.9 mg/dL and Apo B 160.5 ± 43.5 mg/dL. The prevalence of the metabolic syndrome was 71.6% (n = 73). The coexistence for the metabolic syndrome increased the severity of the lipid abnormalities (ie higher triglycerides (201 ± 138 vs 309 ± 166 mg/dL, p < 0.001) and lower HDL-C (46.2 ± 15.7 vs 37 ± 8.1 mg/dL p < 0.001). These coronary event. differences remained statistically significant after adjusting for age, BMI and gender . Conclusion: The prevalence of the metabolic syndrome in FCHL is higher than the reported in Mexican urban adults. The coexistence of the metabolic syndrome in FCHL cases exacerbates hypertriglyceridemia and hypoalfalipoproteinemia.

REFERENCES

1. Goldstein JL, Schrott HG, Hazzard WT et al. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipids levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clinic Invest 1973; 52: 1544-1568.

2. Davignon J, Genest J. Genetic of lipoprotein disorders. Endocrinol Metab Clin North Am 1998; 27: 521-534.

3. Hopkins P, Heiss G, Ellison C, Province M, Pankow J, Eckfeldt J, Hunt S. Coronary artery disease in familial combined hyperlipidemia and familial hypertriglyceridemia. Circulation 2003; 108: 519-523.

4. Bredie SJ, Demacker PN, Stalhenoaf AF. Metabolic and genetic aspects of familial combined hyperlipidemia with emphasis on low density lipoprotein heterogenicity. Eur J Clin Invest 1997; 27: 802-811.

5. Del Rincón-Jarero JP, Aguilar-Salinas CA, Guillén-Pineda LE, Gómez-Pérez FJ, Rull JA. Lack of agreement between the plasma lipid based criteria and the apoprotein B for the diagnosis of Familial Combined Hyperlipidemia (FCHL) in members of FCHL kindreds. Metabolism 2002; 51: 218-224.

6. De Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol 1998; 9: 189-196.

7. Mc Neely M, Edwards K, Marcovina S, Brunzell J, Motulsky A, Austin M. Lipoprotein and apolipoliprotein abnormalities in familial combined hyperlipidemia. Atherosclerosis 2001; 159: 471-481.

8. Fredie SJ, van Drongelen J, Kiemeney LA Demacker PN, Beaty TH, Stalenhoef AF. Segregation analysis of plasma apolipoprotein B leveis in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17: 834-840.

9. Valles V, Aguilar-Salinas CA, Gómez-Pérez FJ, Rojas R, Franco A, Olaiz G, Rull JA, Sepúlveda J. Apolipoprotein B and AI distribution in the Mexican urban adults: Results of a Nation-Wide Survey. Metabolism 2002; 51: 560-568.

10. Sniderman AD, Ribalta J, Castro CM. How should FCHL be defined and how should we think about its metabolic bases? Nutr Metab Cardiovasc Dis 2001; 11: 259-273.

11. Castellani LW, Weinreb A, Bodnar J, Gotto AM, Doolittle M, Mehrabian M, Demant P, Lusis AJ. Mapping a gene for combined hyperlipidemia in a mutant mouse strain. Nat Genet 1998; 18: 374-377.

12. Wijsman EM, Brunzell JD, Jarvik GP, Austin MA, Motulsky AG, Deeb SS. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol 1998; 18: 215-226.

13. Ribalta J, La Ville AE, Vallve JC, Humphries S, Turner PR, Masana L. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J Lipid Res 1997; 38: 1061-1069.

14. Pihlajamaki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17: 1039-1044.

15. Tahvanainen E, Pajukanta P, Porkka K, Nieminen S, Ikavalko L, Nuotio I, Taskinen MR, Peltonen L, Ehnholm C. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1998; 18: 1810-1817.

16. Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, Parkkonen M, Hartiala J, Ylitalo K, Pihlajamaki J, Porkka K, Laakso M, Viikari J, Ehnholm C, Taskinen MR, Peltonen L. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet 1999; 64: 1453-1463.

17. Ascaso JF, Sales J, Merchante A, Real J, Lorente R, Martinez-Valls J, Carmena R. Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia. Int J Obes Relat Metab Disord 1997; 21: 360-366.

18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.

19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings of the Third National Health and Nutrition Examination Survey. JAMA 2002: 287-356.

20. Aguilar-Salinas CA et al. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: Results from a population-based survey. Diabetes Care 2003; 26: 1635.

21. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, Olaiz G, Rull JA, Sepúlveda J. Prevalence of the metabolic syndrome in Mexico: Results from a Population Based Survey. Arch Med Res 2004; 35:76-81.

22. Austin MA, McKnight B, Edwards KL et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20 year prospective study. Circulation 2000; 101: 2777-2782.